0000000001063201

AUTHOR

Jayne S. Gurtler

showing 1 related works from this author

Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advance…

2016

TPS4134Background: Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers. Avelumab* is a fully human anti-PD-L1 ...

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybiologybusiness.industryLocally advancedbiology.organism_classificationAvelumab03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemOncologyMaintenance therapyJavelin030220 oncology & carcinogenesisInternal medicinemedicineIn patientFirst line chemotherapyReceptorbusinessmedicine.drugJournal of Clinical Oncology
researchProduct